Data from sequence analysis, genotyping by restriction fragment length polymorphism in the 5 noncoding region, and NS4 serotyping of the sera of 20 patients with chronic hepatitis C virus infection have shown 100% concordance, while core-based methods and a line probe assay have shown several missing or wrong results.
Since the isolation and recognition in 1989 of the hepatitis C virus (HCV) as the agent responsible for most cases of non-A, non-B hepatitis (1, 5, 10) , several studies have demonstrated a high nucleotide sequence variability in its RNA genome. At least six major HCV genotypes (designated 1 to 6) which differ in nucleotide sequence by more than 30% over the complete virus genome have been described, and a number of subtypes differing by more than 20% in sequence (designated 1a to 1c, 2a to 2c, 3a and 3b, 4a to 4f, 5a, and 6a) have been discovered (the discovery of new subtypes is expected) (16, 21, 22) . Furthermore, the description and classification of new variants is under investigation. In addition, studies of possible correlations between different genotypes and both the evolution of liver damage and the response to antiviral treatment have shown that HCV 1b is more frequently found in patients with elevated aminotransferase levels and evidence of chronic liver disease (20, 24) and that infection by HCV 1b is less responsive to antiviral therapy than that by other subtypes (4, 9, 15, 25) . However, there are still some controversies about the prognostic significance of genotypes for disease outcome (7) .
In addition to HCV sequence analysis, several methods have been developed for HCV typing (6, 14, 17, 18, 23) . Several authors have recently reported partial comparisons of some of these methods (8, 12, 13, 26) , but some discrepancies have been observed in their results, and a more complete study is required. For this reason, the aim of this study was to investigate the accuracy of the methods currently most used (amplification with subtype-specific primers, hybridization with subtype-specific oligonucleotide probes, restriction fragment length polymorphism [RFLP] analysis, and serological response to synthetic peptides) for predicting HCV genotypes and subtypes in several regions of the HCV genome (5Ј noncoding [5ЈNC], core, and NS4), as well as to compare the results of these methods with data obtained by sequence analysis in the 5ЈNC and core regions of HCV.
To this end, we have analyzed the sera of 20 patients with histologically proven chronic active hepatitis due to HCV infection. All of them had anti-HCV antibodies, as detected by ELISA III (Ortho Diagnostic Systems, Raritan, N.J.) and confirmed by RIBA III (Ortho). The criterion used to select these patients was the presence of HCV RNA in serum, as detected by reverse transcription (RT)-PCR after HCV RNA extraction by using the guanidinium isothiocyanate method (3) with primers from the 5ЈNC region of the HCV genome as previously described (14) . In addition, quantitation of HCV RNA in copies per milliliter with the Amplicor HCV Monitor assay (Roche Diagnostic Systems, Inc., Branchburg, N.J.) was performed in duplicate. To avoid false-positive results, the contamination prevention measures of Kwok and Higuchi (11) were followed, and negative controls were included in all experiments. Genotyping by each method tested was performed in duplicate for all samples, and concordant results were obtained in each case.
Core genotyping. HCV genotyping by amplification in the core region of the HCV genome was performed in three ways: (i) as previously described by Okamoto et al. (named Core A ) (17) , with a mixture of one universal sense primer and four antisense subtype-specific primers (for 1a, 1b, 2a, and 2b subtypes); (ii) according to the revised method described by Okamoto et al. (named Core   B ) (18) , improved to detect HCV subtypes 1a, 1b, 2a, 2b, and 3a; and (iii) by using a modification of this method which consists of the amplification of each HCV subtype with the same primers as those of the Core A or Core B method but in independent nested PCRs, one for each subtype. The latter modification was performed for the two corebased methods. All PCR products were visualized by polyacrylamide gel electrophoresis and ethidium bromide staining. By using the Core A assay, a high proportion of untyped samples was found (7 of 20; 35%) ( 5NC region genotyping. HCV genotyping was also performed in the 5ЈNC region of the HCV genome in three ways: (i) by using the line probe assay (INNO-LIPA; Innogenetics NV, Zwijnaarde, Belgium), version II, in which oligonucleotide probes derived from the 5ЈNC region are hybridized with the biotinylated nested-PCR products (23); (ii) by amplification with universal primers followed by RFLP analysis of the radiolabelled [
32 P]dATP nested-PCR products, as previously described by McOmish et al. (14) ; and (iii) by an alternative RFLP-typing scheme with the same PCR products as in (ii) above in two consecutive enzymatic reactions in order to discriminate among HCV types 1 to 6, the first reaction being performed with the enzyme MboI and the second, if needed, being performed with FokI plus Alw26I or with HaeIII plus Alw26I (electrophoretic patterns are shown in Fig. 1 ). Since HCV types 5 and 6 were not found in our population, their electrophoretic patterns were studied by computer analysis of theoretical digestions in published sequences obtained from the GenBank database. In the enzymatic digestions, 4 l of nested-PCR products was incubated overnight at 37ЊC with 10 U of the corresponding restriction enzymes (Promega Corp., Madison, Wis.). The differences in the sizes of digested DNA were resolved by 12% polyacrylamide gel electrophoresis followed by autoradiography.
By using the line probe assay (LIPA), the detection of HCV genotypes and subtypes was as follows: 1b, 10 of 20 (50%); 1a, 3 of 20 (15%); type 1 without defined subtype, 2 of 20 (10%); 2a, 1 of 20 (5%); type 3 without defined subtype, 2 of 20 (10%); and undetermined, 2 of 20 (10%) ( Table 1) . Genotyping by 5ЈNC RFLP analysis with the two alternative RFLP-typing schemes showed 100% concordance between them. Genotype determinations were as follows: HCV type 1, 15 of 20 (75%); HCV type 2, 1 of 20 (5%); HCV type 3, 3 of 20 (15%); and HCV type 4, 1 of 20 (5%). Mixed infections (1a plus 1b) were suspected in two cases. Genotyping by 5ЈNC RFLP analysis and LIPA methods differed in 20% of the samples (4 of 20), and the differences observed were as follows: for two of the four samples, HCV type 1 detected by RFLP assays was not recognized by LIPA (unknown genotype); the two other samples (one HCV type 3 and one HCV type 4 by 5ЈNC RFLP methods) were recognized as HCV 1 by LIPA (Table 1) .
Subtyping by 5NC RFLP. Subtyping of samples with genotype 2 or 3 was performed as described by Davidson et al. (6) , giving subtype 2a for a sample with genotype 2 and 3a for the three samples with type 3. HCV 1a and 1b subtyping was carried out using three restriction enzymes: BstUI (New England Biolabs, Beverly, Mass.) as previously described (6), MvnI (isoschizomer of BstUI) (Boehringer GmbH, Mannheim, Germany), and Alw26I (Promega Corp.) (generating two fragments for HCV 1b [175 and 76 bp] but no digestion of HCV 1a).
HCV 1a and 1b subtyping of the 15 samples having type 1 with the enzyme BstUI gave clear electrophoretic patterns in all but one (sample 17), in which the digestion showed an inconclusive 1a-1b electropherotype (presence of electrophoretic bands of 210, 180, 41, and 30 bp). When HCV 1a and 1b subtyping was performed with MvnI, almost all of the samples gave inconclusive results. In contrast, when Alw26I was used to differentiate between 1a and 1b subtypes, inconclusive electropherotypes were observed in only two samples (16 and 17; presence of electrophoretic bands of 251, 175, and 76 bp). These inconclusive electropherotypes might reflect, for BstUI and Alw26I, the existence of an undigested PCR product of the 1b subtype or a real mixed infection (HCV 1a plus 1b).
Subtyping by both RFLP methods and LIPA differed in 2 of the 16 samples with identical genotypes. For one sample, the HCV subtype was 1a by 5ЈNC RFLP but was subtype 1b by LIPA; for another, the HCV was 1a plus 1b by 5ЈNC RFLP, but was HCV 1b alone by LIPA (Table 1) . In summary, excluding the Core B assay (which appears to be almost useless for typing since it detected mixed infections and could not identify 19 of 20 specimens), only 8 of 20 (40%) serum samples analyzed gave concordant results with all the methods applied (Core A assay, LIPA, 5ЈNC RFLP as described by Davidson et al. [6] , and modified 5ЈNC RFLP as described in this paper).
Sequence analysis. As the definitive approach to the investigation of discrepant results among different methods in HCV genotyping, sequence analysis was performed after amplification on the 5ЈNC region and the core gene (nucleotides 259 to 492) of the HCV genome (outer primers: sense, 5Ј-CTGTGA GGAACTACTGTCTT-3Ј, and antisense, 5Ј-RAAGATAGA RAARGAGCAACCKGG-3Ј; inner primers: sense, 5Ј-TTCA CGCAGAAAGCGKCTAG-3Ј, and antisense, 5Ј-CCRGGNA (21) have reported that approximately 2 to 5% of the 5ЈNC sequences of HCV genotype 1 may have a mutation in nucleotide 99 which could induce a false 1a-1b subtyping. In our study, this change was not observed. Figure 2 shows the alignment of the consensus sequences of the 5ЈNC and core regions of subtypes 1a and 1b (2), with the consensus sequences obtained for each subtype in the two samples with coinfection 1a plus 1b. The sequence divergences in the core region (nucleotides 1 to 492) among consensus sequences of subtypes 1a and 1b (2) and sequences obtained of subtypes 1a and 1b in samples 16 and 17 were studied ( Table 2) . As expected, the divergences observed between sequences of the same subtype were smaller than those observed between sequences of different subtypes.
Because RFLP with BstUI subtyped sample 16 as infected only with HCV 1b (not revealing the presence of HCV 1a), all the 801-bp clones obtained from this sample were subjected to amplification of the 5ЈNC region (6) and the PCR products were subtyped again with BstUI. In all cases, the enzyme gave the expected electrophoretic pattern according to the subtypes deduced by sequencing. Thus, we do not have an explanation for the lack of detection of a mixed infection by BstUI subtyping in the original PCR product of this patient.
In the five samples with discrepancies in genotyping or subtyping results between the 5ЈNC RFLP and LIPA methods (samples 2, 3, 6, 7, and 14), the sequencing results demonstrated that these five samples (one with subtype 3a, one with genotype 4, two with subtype 1b, and one with subtype 1a) were erroneously recognized as HCV 1b, type 1, or not identified by LIPA, while both 5ЈNC RFLP analyses gave the correct results. The 5ЈNC sequences of these samples presented the corresponding consensus type motifs of each genotype or subtype, without any mutation which could justify theoretical hybridization with LIPA HCV 1b probes or the lack of hybridization with the corresponding oligonucleotide probes.
Sequence analysis of those samples with discrepancies between the 5ЈNC RFLP, LIPA, and Core A methods showed 100% concordance between the HCV type demonstrated by sequencing and the type assigned by the 5ЈNC RFLP and LIPA methods. Thus, HCV types 2a and 3a were mistyped by Core A as HCV 1b (samples 19 and 3) or HCV 1a plus 1b (sample 18). Furthermore, in several samples, the Core A assay failed to recognize HCV 1b (sample 2), HCV 1a (sample 13), or HCV 1a plus 1b (sample 16) and mistyped HCV 1b (samples 11 and In addition to the lack of specificity reported above in the type-specific primer corresponding to 1a, it is worth noting that the Core B type primer used for detection of HCV 3a amplified nonspecifically both HCV 1a (sample 1) and HCV 1b (sample 20). This lack of type specificity was experimentally assessed by means of PCR with HCV 1a and HCV 1b plasmids (containing 5ЈNC and core regions of the HCV genome). In both cases, a false HCV 3a fragment (84 bp) was obtained.
NS4 serotyping. Serological response of the host to virus infection was also studied by using a commercial enzyme immunoassay which employed synthetic NS4 peptides (Murex Diagnostics Limited, Dartford, United Kingdom). The results obtained for 5ЈNC RFLP genotyping and for NS4 serotyping showed a concordance of 100%.
Relation between HCV genotypes and viremia. Some authors have reported a correlation between infection by virus with the HCV 1b genotype and the presence of high titers of virus in serum (19) . In spite of the small number of samples analyzed in this study, we have evaluated the possible relationship between the viral load in each sample (expressed as the average of two determinations, in copies per milliliter) (Table  1 ) and the real HCV genotype. Statistical analysis has been performed with the nonparametric Wilcoxon's rank sum test for comparison of two groups of independent samples. Thus, the viral load of samples with genotypes 2, 3, or 4 (taken together) showed a statistically significant lower value than those with genotype 1 (P Ͻ 0.05), and samples with genotypes 1a, 2, 3, or 4 (taken together) also showed a statistically significant lower viral load than those infected with genotype 1b only (P Ͻ 0.05). In addition, samples with genotype 3 showed a statistically significant lower viral load than those with genotype 1 or with genotype 1b only (P Ͻ 0.05 in both cases).
It is not likely that the statistically significant differences reported above are due to a possible difference in the efficiencies of amplification of the genotypes by the set of primers used in the Amplicor HCV Monitor assay, since these are almost completely conserved among the sequences reported for each HCV genotype, with the sole exception of two polymorphic sites in the sense primer KY80 (27) .
Conclusions. Considering the genotyping and serotyping results as a group, it is remarkable that data from sequence analysis, genotyping by RFLP in the 5ЈNC region in the two typing schemes tested, and serotyping with peptides derived from the NS4 region showed a 100% concordance. Accordingly, 5ЈNC RFLP analysis seems to be the most accurate method for HCV genotyping (Table 3 ). In contrast, LIPA II failed to recognize the real genotype in one case each of samples with HCV types 1a, 1b, 3a, and 4 and was unable to detect the two cases with coinfection 1a plus 1b. Furthermore, the Core A typing method failed to recognize the real genotype in one sample with HCV 1a, in three samples with HCV 1b, in the a HCV 1a and HCV 1b refer to the consensus sequences of the core regions of subtypes (2) . n, number of clones typed as 1a or 1b in each sample analyzed. 9 (100) 7 (78) 15 (100) 6 (67) 1a ϩ 1b (n ϭ 2) 2 (100) b 0 (0) 0 (0) 2a (n ϭ 1) 1 (100) 1 (100) 1 (100) 0 (0) 3a (n ϭ 3) 3 (100) 2 (67) 3 (100) 4 (n ϭ 1) 1 (100) 0 (0) 1 (100) a NS4 serotypes can be related only to HCV genotypes, not to subtypes. b One of these coinfections was detected by the 5ЈNC RFLP analysis only when using the enzyme Alw26I instead of BstUI in order to differentiate between the 1a and 1b subtypes.
sample with HCV 2a, and in the two samples with coinfection HCV 1a plus 1b.
Finally, although there was a 100% concordance between 5ЈNC RFLP and NS4 serotyping, the fact that serotyping cannot discriminate between HCV subtypes makes this method less useful than RFLP analysis in the 5ЈNC region. With respect to the latter method, the typing scheme proposed in this study, based on a first digestion with the enzyme MboI, is as efficient as that previously reported by McOmish et al. (14) , but its requirement of a lesser number of enzymatic reactions makes the MboI-based method more advisable.
